SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending due to a recently announced $1.5 billion public offering, leading to community concern about potential dilution and criticism of management. Some investors view the drop as a buying opportunity, while others express frustration, especially given anticipation around potential S&P 500 inclusion. The offering's impact on the stock's short-term and long-term prospects is a key point of discussion.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending due to a recent public offering, leading to discussions about dilution and its impact on the stock's future. While some investors express concerns about short-term pain, others view the offering as a strategic move to strengthen the company's balance sheet and fund expansion. Community sentiment appears divided, with bulls anticipating long-term gains and bears pointing to potential downside risks.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies ($QCLS) is trending due to investor Martin Shkreli announcing a position in the company with a bold price target, sparking community discussion around a potential short squeeze. Traders are actively comparing $QCLS to other recent runners like $SMX and debating the company's potential in the photonics sector. Bullish sentiment is building, with many anticipating a continued upward trend and significant gains.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to a significant short squeeze, leading to massive gains and high volatility. Community discussions revolve around the potential for further upside and comparisons to other recent low-float runners, while some traders are identifying potential sympathy plays in similar sectors.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is trending due to community excitement around its low float and potential for a significant price surge, drawing comparisons to other stocks with similar setups. Discussions highlight the stock's accumulation patterns and potential breakout points, with some anticipating a rapid climb. However, some caution against chasing the stock and highlight the company's fundamentals and financial position.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is trending amid discussions around its upcoming earnings report, with community members debating potential outcomes and comparing it to competitor CrowdStrike. A change in CFO, and a beat in free cash flow are being discussed as reasons to be bullish. Some traders anticipate a significant move, while others remain skeptical due to the stock's historical performance after earnings releases.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics is trending as investors discuss the potential for FDA guidance by year-end and speculate on the possibility of a buyout or partnership. Community members are focused on positive biomarker data and what it could mean for the company's future. Discussions also involve short positions, trading activity, and the potential for a squeeze.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending amid a recent earnings report and subsequent analyst activity, with the community debating the stock's valuation and future potential. Despite positive financial results, the stock experienced selling pressure, leading to discussions about market sentiment and possible bottom fishing. Some investors view Rubrik as a long-term hold in the cybersecurity space, particularly due to its AI capabilities and partnerships, while others express concerns about insider selling and overall market conditions.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending as discussions revolve around a recent acquisition of a copper powder stockpile, with some questioning its strategic value and others seeing it as a positive step for securing supply chains. Bullish sentiment is fueled by hopes for the upcoming BFS and potential government support, while bearish voices express concern over the CEO's credibility. Community members are actively debating the merits of this acquisition and its implications for the company's future.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending amid discussions about its recent earnings and future prospects, with community members debating whether a double beat justifies its current price. Bullish investors highlight the company's free cash flow and potential for a short squeeze, while others express concerns about guidance and competition. Some traders are eyeing specific price points and option strategies, adding to the stock's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


HLGN
Heliogen Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HLGN News

HLGNHeliogen Inc - Ordinary Shares - Class A